Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.0%. By the end of trading, Alexion Pharmaceuticals fell $2.15 (-2.3%) to $90.45 on average volume. Throughout the day, 2,626,691 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,925,200 shares. The stock ranged in price between $88.86-$93.17 after having opened the day at $92.61 as compared to the previous trading day's close of $92.60. Other companies within the Drugs industry that declined today were: Oxygen Biotherapeutics ( OXBT), down 8.4%, Biostar Pharmaceuticals ( BSPM), down 8.3%, Anacor Pharmaceuticals ( ANAC), down 7.9% and Bacterin International Holdings ( BONE), down 7.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $17.9 billion and is part of the health care sector. The company has a P/E ratio of 71.9, above the S&P 500 P/E ratio of 17.7. Shares are down 1.8% year to date as of the close of trading on Friday.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, ARCA biopharma ( ABIO), down 47.2%, Tranzyme ( TZYM), down 25.7%, Catalyst Pharmaceutical Partners ( CPRX), down 20.2% and MediciNova ( MNOV), down 12.6% , were all gainers within the drugs industry with Pharmacyclics Incorporated ( PCYC) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk